NCT06788522View on ClinicalTrials.gov

The Effects of Orexin Antagonism on Fear Extinction in PTSD

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

40,120

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

March 1, 2032

Study Completion Date

June 30, 2032

Conditions
InsomniaPTSD
Interventions
DRUG

Suvorexant

Suvorexant pills (10-20 mg)

DRUG

Placebo

Matching placebo pills

Trial Locations (2)

94121-1563

San Francisco VA Medical Center, San Francisco, CA, San Francisco

29401-5703

Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston

All Listed Sponsors
lead

VA Office of Research and Development

FED